Safety and tolerability of fedratinib (FEDR), an oral inhibitor of janus kinase 2 (JAK2), in patients with intermediate- or high-risk myelofibrosis (MF) previously treated with ruxolitinib (RUX): results from the phase 3b FREEDOM trial
Last Updated: Monday, January 10, 2022
Results from the phase 3b FREEDOM trial—presented during the 2021 American Society of Hematology Annual Meeting—show that the use of fedratinib among patients with intermediate- or high-risk myelofibrosis previously treated with ruxolitinib is well tolerated. Most gastrointestinal (GI) adverse events (AEs) were grade 1/2, and there were no treatment-related grade 3/4 GI AEs, but frequency and severity of GI AEs may be reduced via early use of GI prophylaxis.
Advertisement
News & Literature Highlights